ArticleBMC microbiology2026
Characterization of a conjugative IncFII/IncR plasmid harboring bla
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCarbapenem-resistant Citrobacter freundii is increasingly reported and recognized as an opportunistic host of mobile carbapenemase-encoding elements in healthcare-associated settings. However, lineage-associated plasmid vehicles and their transfer-related features in this species remain incompletely characterized.
objectiveThis study aims to characterize the first IncFII(pBK30683)/IncR plasmid carrying blaKPC-2 in C. freundii ST91, focusing on its transferability, stability, and the role of plasmid lineages in carbapenem resistance dissemination.
methodsWe investigated a urine-derived ST91 C. freundii isolate (MAS5905) through antimicrobial susceptibility testing, whole-genome sequencing, conjugation, 20-day plasmid stability, and growth curve assays. Comparative genomics included plasmid phylogeny of pMAS5905-KPC-like sequences and ST91 phylogenomics.
resultsThe 5.64 Mb genome comprised a chromosome and three plasmids. blaKPC-2 was located on an IncFII(pBK30683)/IncR plasmid pMAS5905-KPC carrying a complete conjugation module, the mer operon, and the anti-CRISPR determinant AcrIE9, with the blaKPC-2 embedded in an IS26-bracketed ΔTn6296-like module (ISKpn27-blaKPC-2-ΔISKpn6). The plasmid transferred to E. coli at 1.93 × 10–5 was retained at 100% over 20 days, and imposed a significant fitness cost. Phenotypically, MAS5905 was resistant to multiple β-lactams (including ertapenem and meropenem) and fluoroquinolones, while remaining susceptible to cefepime, ceftazidime, trimethoprim-sulfamethoxazole, aminoglycosides, tetracyclines, and nitrofurantoin. Plasmid comparisons resolved six IncFII/IncR clades with a conserved backbone and broad host range. ST91 phylogenomics revealed multiple clades and, in the analyzed public dataset, a high carbapenemase gene prevalence (75.76%), dominated by blaKPC (31.82%) and blaOXA-48-like (30.30%).
conclusionTo our knowledge, this is the first characterization of an IncFII(pBK30683)/IncR plasmid carrying blaKPC-2 in a clinical C. freundii ST91 isolate. The findings highlight plasmid lineages as drivers of carbapenem resistance dissemination and underscore the need for plasmid-focused genomic surveillance, particularly for monitoring transferable resistance vehicles across clinically relevant hosts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.